杜皮鲁玛
皮肤病科
医学
系列(地层学)
病理
生物
特应性皮炎
古生物学
作者
Agnieszka Dybała,Alvise Sernicola,Vito Gomes,Giorgia Carnicelli,Rovena Muharremi,Teresa Grieco
出处
期刊:Immunotherapy
[Future Medicine]
日期:2021-12-22
卷期号:14 (4): 183-188
被引量:11
标识
DOI:10.2217/imt-2021-0122
摘要
Dupilumab-related head and neck dermatitis is an increasingly reported clinical manifestation occurring in 4-10% of patients on dupilumab that was apparently not reported in clinical trials. Out of 62 adult patients treated with dupilumab for atopic dermatitis in the authors' center, four cases (6%) of head and neck dermatitis were observed, for which a skin biopsy was obtained. Onset occurred between 8 and 24 weeks after initiation of dupilumab, and the reaction resolved after 8-12 weeks. Histopathology and immunohistochemical findings support the authors' hypothesis that facial redness may be a toxic effect induced by dupilumab, although its pathogenesis still requires further investigation.
科研通智能强力驱动
Strongly Powered by AbleSci AI